Kelly, W K <br/><br/>
The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Mar 2000 
 - 838-46 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antigens, Surface<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Biopsy<br/>Bone Neoplasms--drug therapy<br/>Carboxypeptidases--analysis<br/>Cheilitis--chemically induced<br/>Dyspnea--chemically induced<br/>Exanthema--chemically induced<br/>Fatigue--chemically induced<br/>Glutamate Carboxypeptidase II<br/>Hematologic Diseases--chemically induced<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--administration & dosage<br/>Ki-67 Antigen--analysis<br/>Liver--enzymology<br/>Male<br/>Middle Aged<br/>Prostate--chemistry<br/>Prostate-Specific Antigen--blood<br/>Prostatic Neoplasms--drug therapy<br/>Recombinant Proteins<br/>Transaminases--drug effects<br/>Treatment Outcome<br/>Tretinoin--administration & dosage